Journal article

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

Gyoergy Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella, Tudor Eliade Ciuleanu, G Pover, NC Tebbutt

Investigational New Drugs | SPRINGER | Published : 2012